US withdrawal from Iran deal can hit Danish companies
The US's withdrawal from the Joint Plan of Action with Iran and the reimposition of sanctions can impact Danish pharmaceutical companies and medico firms, writes the Danish interest group Dansk Industri. Novo Nordisk, which has invested DKK 500 million (EUR 67 million) in Iran, awaits further developments.
President Trump's decision to withdraw the US from the Joint Plan of Action (JPA) with Iran can end up damaging Danish pharmaceutical companies and medico firms with assets in Iran – including Novo Nordisk.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s US head is ready for turnaround
For abonnenter
